©The Author(s) 2016.
World J Clin Cases. Oct 16, 2016; 4(10): 310-317
Published online Oct 16, 2016. doi: 10.12998/wjcc.v4.i10.310
Published online Oct 16, 2016. doi: 10.12998/wjcc.v4.i10.310
Table 1 Patient demographic characteristics
| n (%) | ||
| Sex | Male | 6 (25.0) |
| Female | 18 (75.0) | |
| Age | Mean (range) | 61.2 ± 11.5 (39-86) |
| Primary tumor | Breast | 11 (45.8) |
| Gynecological | 4 (16.7) | |
| Hematological | 3 (12.5) | |
| Gastrointestinal | 3 (12.5) | |
| Others | 3 (12.5) | |
| Responsible chemotherapeutic agents (overlapping, see Table 4) | Taxanes | 15 (62.5) |
| Platinum analogues | 7 (29.2) | |
| Vinca alkaloids | 3 (12.5) | |
| Bortezomiib | 3 (12.5) | |
| Duration until starting Kampo medicine after responsible chemotherapy | During chemotherapy | 6 (25.0) |
| < 6 mo after | 8 (33.3) | |
| 7-12 mo after | 4 (16.7) | |
| > 13 mo after | 6 (25.0) | |
- Citation: Kimata Y, Ogawa K, Okamoto H, Chino A, Namiki T. Efficacy of Japanese traditional (Kampo) medicine for treating chemotherapy-induced peripheral neuropathy: A retrospective case series study. World J Clin Cases 2016; 4(10): 310-317
- URL: https://www.wjgnet.com/2307-8960/full/v4/i10/310.htm
- DOI: https://dx.doi.org/10.12998/wjcc.v4.i10.310